Meet Velico at upcoming conferences across North America and Europe and learn more about our FrontlineODP™ Spray Dried Plasma Manufacturing System. America’s Blood Centers (ABC) Annual Meeting, Tucson, Arizona (Mar 9–12) | DMHD – Defense Medical & Health Delivery Conference, London, UK (Mar 24–25)
#PlasmaEverywhere
Velico’s® spray dried plasma manufacturing technology platform, the FrontlineODPTM (On Demand Plasma) system, is fast becoming the leading dried plasma production platform worldwide. Intuitive operation, high throughput and a small footprint optimally position the FrontlineODPTM system for any blood component production environment.
FrontlineODPTM (On Demand Plasma)
FrontlineODPTM Manufacturing System turns liquid plasma into a spray dried powder in approximately 35 minutes. The spray dried powdered plasma is easy to store, transport, and rehydrates when needed with just 200ml of sterile water.
European CE Mark Application Planned for Q4 2026
Velico® is pursuing regulatory approval in Europe and around the world. The company has successfully completed a first-in-human clinical study evaluating the safety of FrontlineODP™ (On Demand Plasma) compared to traditional frozen plasma. Velico is now advancing its European regulatory pathway, with submission for CE Mark certification as a Class IIb medical device planned by the end of Q4 2026. Subject to successful conformity assessment, CE Mark certification for the system is targeted for Q3 2027.
Key findings: all 24 completed; infusions well tolerated; no thromboembolic events; treatment-emergent adverse events similar to frozen plasma; minor non-significant coagulation changes; protein preservation in the FrontlineODPTM (On Demand Plasma) system successfully demonstrated.
Manufacturing
Velico® is expanding manufacturing globally. Currently, our facility produces up to 100,000 PDC units annually, with planned expansion to 250,000 units per facility by 2030. Additional units are planned over the coming years in order to facilitate demand.
